Literature DB >> 14744934

Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis.

Chun-Ming Chen1, Richard R Behringer.   

Abstract

Loss of OVCA1/DPH2L1 correlates with ovarian and breast cancer. To study its in vivo role, we generated Ovca1 mutant alleles in mice. Ovca1 heterozygotes spontaneously develop cancer. Ovca1 mutant mice die during embryonic development and at birth with developmental delay and defects in multiple organ systems. Cell proliferation defects were observed in Ovca1 mutant mouse embryonic fibroblasts (MEFs). p53 deficiency can rescue these Ovca1 mutant MEF proliferation defects and partially rescue Ovca1 mutant embryonic phenotypes. Furthermore, Ovca1; p53 double heterozygotes developed tumors quicker than p53 heterozygotes and with an increased carcinoma incidence. Multiple tumor burden in Ovca1 heterozygotes that were also p53 deficient was significantly higher than in p53 homozygous mutants. These in vivo findings demonstrate that Ovca1 is a tumor suppressor that can modify p53-induced tumorigenesis and suggest that it acts as a positive regulator for cell cycle progression. The close linkage of OVCA1 and p53 on human Chromosome 17 suggests that coordinated loss may be an important mechanism for the evolution of ovarian, breast, and other tumor phenotypes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744934      PMCID: PMC338284          DOI: 10.1101/gad.1162204

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  44 in total

1.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.

Authors:  C Kuperwasser; G D Hurlbut; F S Kittrell; E S Dickinson; R Laucirica; D Medina; S P Naber; D J Jerry
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

2.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

3.  Allelic imbalance and fine mapping of the 17p13.3 subregion in sporadic breast carcinomas.

Authors:  C Hoff; J Mollenhauer; B Waldau; U Hamann; A Poustka
Journal:  Cancer Genet Cytogenet       Date:  2001-09

4.  Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells.

Authors:  S O'Gorman; N A Dagenais; M Qian; Y Marchuk
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

5.  Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.

Authors:  S A Gayther; J Mangion; P Russell; S Seal; R Barfoot; B A Ponder; M R Stratton; D Easton
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

6.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2.

Authors:  S K Sharan; M Morimatsu; U Albrecht; D S Lim; E Regel; C Dinh; A Sands; G Eichele; P Hasty; A Bradley
Journal:  Nature       Date:  1997-04-24       Impact factor: 49.962

7.  Allelic loss on chromosome 17 in human ovarian cancer.

Authors:  N Phillips; M Ziegler; B Saha; F Xynos
Journal:  Int J Cancer       Date:  1993-04-22       Impact factor: 7.396

8.  Evidence for a second tumor suppressor gene on 17p linked to high S-phase index in primary human breast carcinomas.

Authors:  G R Merlo; T Venesio; A Bernardi; C S Cropp; F Diella; A P Cappa; R Callahan; D S Liscia
Journal:  Cancer Genet Cytogenet       Date:  1994-09

9.  Identification of two candidate tumor suppressor genes on chromosome 17p13.3.

Authors:  D C Schultz; L Vanderveer; D B Berman; T C Hamilton; A J Wong; A K Godwin
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

10.  Detection of human papillomavirus-16 in ovarian malignancy.

Authors:  Q-J Wu; M Guo; Z-M Lu; T Li; H-Z Qiao; Y Ke
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

View more
  49 in total

1.  OVCA1 inhibits the proliferation of epithelial ovarian cancer cells by decreasing cyclin D1 and increasing p16.

Authors:  Fandou Kong; Rui Tong; Lingyu Jia; Wei Wei; Xiaoyan Miao; Xinyu Zhao; Wenping Sun; Guang Yang; Chunyan Zhao
Journal:  Mol Cell Biochem       Date:  2011-04-13       Impact factor: 3.396

2.  Chemogenomic approach identified yeast YLR143W as diphthamide synthetase.

Authors:  Xiaoyang Su; Zhewang Lin; Wei Chen; Hong Jiang; Sheng Zhang; Hening Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-19       Impact factor: 11.205

3.  Dph3, a small protein required for diphthamide biosynthesis, is essential in mouse development.

Authors:  Shihui Liu; Jason F Wiggins; Taduru Sreenath; Ashok B Kulkarni; Jerrold M Ward; Stephen H Leppla
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

4.  Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Authors:  Xiaodong Ma; Saibyasachi N Choudhury; Xiang Hua; Zhongping Dai; Yong Li
Journal:  Carcinogenesis       Date:  2013-02-05       Impact factor: 4.944

5.  Identification of the proteins required for biosynthesis of diphthamide, the target of bacterial ADP-ribosylating toxins on translation elongation factor 2.

Authors:  Shihui Liu; G Todd Milne; Jeffrey G Kuremsky; Gerald R Fink; Stephen H Leppla
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

6.  Genome-Wide CRISPR Screening Identifies the Tumor Suppressor Candidate OVCA2 As a Determinant of Tolerance to Acetaldehyde.

Authors:  Amin Sobh; Alex Loguinov; Alessia Stornetta; Silvia Balbo; Abderrahmane Tagmount; Luoping Zhang; Chris D Vulpe
Journal:  Toxicol Sci       Date:  2019-05-01       Impact factor: 4.849

7.  Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients.

Authors:  Yi-Jen Chen; Chun-Ming Chen; Nae-Fang Twu; Ming-Shyen Yen; Chiung-Ru Lai; Hua-Hsi Wu; Peng-Hui Wang; Chiou-Chung Yuan
Journal:  Virchows Arch       Date:  2009-10-17       Impact factor: 4.064

8.  A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.

Authors:  Hui Wei; Tapan K Bera; Alan S Wayne; Laiman Xiang; Simona Colantonio; Oleg Chertov; Ira Pastan
Journal:  J Biol Chem       Date:  2013-03-13       Impact factor: 5.157

Review 9.  Molecular basis of cleft palates in mice.

Authors:  Noriko Funato; Masataka Nakamura; Hiromi Yanagisawa
Journal:  World J Biol Chem       Date:  2015-08-26

10.  Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development.

Authors:  Tom R Webb; Sally H Cross; Lisa McKie; Ruth Edgar; Lucie Vizor; Jackie Harrison; Jo Peters; Ian J Jackson
Journal:  J Cell Sci       Date:  2008-09-02       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.